BIOV — BioVersys AG Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeSmall Cap
- CH₣160.82m
- CH₣182.55m
- CH₣0.80m
Annual income statement for BioVersys AG, fiscal year end - December 31st, CHF millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 0 | 0 | 0.8 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Other Operating Expenses | |||
| Total Operating Expenses | 17.7 | 18.7 | 20.8 |
| Operating Profit | -17.7 | -18.7 | -20 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -18.3 | -18.7 | -21.8 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -18.3 | -18.7 | -21.8 |
| Net Income Before Extraordinary Items | |||
| Net Income | -18.3 | -18.7 | -21.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -18.3 | -18.7 | -21.8 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -56.5 | -57 | -3.73 |